Anti-tumor effects in combination with PARP inhibitor and DNMT inhibitor in ovarian cancer

被引：0
|
作者：
Lee, Jeong-Won [1 ]
Jeong, Soo Young [1 ]
Ryu, Ji Yoon [1 ]
Lee, Yoo-Young [1 ]
Esun, Paik [1 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-377
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
377
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The role of PARP inhibitor combination therapy in ovarian cancer
    Hockings, Helen
    Miller, Rowan E.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [2] An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
    Xu, Jing
    Gao, Yi
    Luan, Xiaotian
    Li, Ke
    Wang, Jing
    Dai, Yilin
    Kang, Mingyi
    Lu, Chong
    Zhang, Minhua
    Lu, Chris X.
    Kang, Yu
    Xu, Congjian
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (05) : 683 - 695
  • [3] An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer
    Jing Xu
    Yi Gao
    Xiaotian Luan
    Ke Li
    Jing Wang
    Yilin Dai
    Mingyi Kang
    Chong Lu
    Minhua Zhang
    Chris X. Lu
    Yu Kang
    Congjian Xu
    Cancer Chemotherapy and Pharmacology, 2022, 89 : 683 - 695
  • [4] In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma
    AlHilli, Mariam M.
    Becker, Marc A.
    Weroha, S. John
    Flatten, Karen S.
    Hurley, Rachel M.
    Harrell, Maria I.
    Oberg, Ann L.
    Maurer, Matt J.
    Hawthorne, Kieran M.
    Hou, Xiaonan
    Harrington, Sean C.
    McKinstry, Sarah
    Meng, X. Wei
    Wilcoxen, Keith M.
    Kalli, Kimberly R.
    Swisher, Elizabeth M.
    Kaufmann, Scott H.
    Haluska, Paul
    GYNECOLOGIC ONCOLOGY, 2016, 143 (02) : 379 - 388
  • [5] Identifying the radiosensitizing effects of PARP inhibitor in ovarian cancer
    Bi, Yue
    Verginadis, Ioannis
    Dey, Souvik
    Guo, Linlang
    Lin, Lilie
    Zheng, Yanfang
    Koumenis, Constantinos
    CANCER RESEARCH, 2017, 77
  • [6] Anti-tumor potential of Hydralazine, a DNMT1 inhibitor, on breast cancer growth and progression
    Patel, Parth B.
    CANCER RESEARCH, 2019, 79 (13)
  • [7] Interleukin-34 cancels anti-tumor immunity by PARP inhibitor
    Nakamura, Takayoshi
    Kajihara, Nabeel
    Hama, Naoki
    Kobayashi, Takuto
    Otsuka, Ryo
    Han, Nanumi
    Wada, Haruka
    Hasegawa, Yoshinori
    Suzuki, Nao
    Seino, Ken-ichiro
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2023, 34 (03)
  • [8] Novel combination therapy of DNMT inhibitor SGI-110 and PARP inhibitor BMN-673 (talazoparib) for BRCA-proficient ovarian cancer
    Pulliam, Nicholas
    Taverna, Pietro
    Lyons, John
    Nephew, Kenneth P.
    CANCER RESEARCH, 2015, 75
  • [9] PARP inhibitor nanotherapy for ovarian cancer
    Baldwin, Paige
    Ohman, Anders
    Thong, Jeremy
    Tangutoori, Shifalika
    Dinulescu, Daniela
    Sridhar, Srinivas
    CLINICAL CANCER RESEARCH, 2016, 22
  • [10] Histone deacetylases inhibitor SAHA enhances anti-tumor effects of poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in breast cancer cells
    Min, A.
    Im, S-A
    Kim, S.
    Song, S-H
    Lee, K-H
    Han, S-W
    Oh, D-Y
    Kim, T-Y
    Bang, Y-J
    CANCER RESEARCH, 2013, 73
12345